South Africa’s leading generic drug manufacturer, Aspen Pharmacare, has issued a stark warning regarding the local production of a breakthrough medical treatment. The company asserts that local firms require guaranteed demand to manufacture the HIV prevention shot lenacapavir sustainably. South Africa was notably absent from the initial round of voluntary licences. In 2024, the patent holder, Gilead Sciences, awarded licences…